Apogee Therapeutics (APGE) Announces Proposed IPO

Apogee Therapeutics (NASDAQ: APGE) has filed for a proposed IPO.

The company describes itself as: 'We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Our two most advanced programs are APG777 and APG808, which we are initially developing for the treatment of AD and COPD, respectively. With our broad pipeline and depth of expertise, we believe we can deliver value and meaningful benefit to patients underserved by today’s standard of care."

Jefferies, TD Cowen, Stifel and Guggenheim Securities will serve as underwriters.

You May Also Be Interested In

• Karman Line Acquisition prices $200M IPO on Nasdaq
• Canaan mined 46 bitcoin in July, holds 1,917 BTC on balance sheet
• Beyond Air, Inc. (XAIR) files for 5.42M share offering by selling stockholders